Individualization of antiretroviral therapy

References

• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsDepartment of Health and Human Services2011166 Available from: http://www.aidsinfo.nih.gov/ContentFiles/Adultand-AdolescentGL.pdf. Accessed September 4, 2011
   Google Scholar
• ThompsonMAbergJCahnPAntiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panelJAMA2010304332133320639566
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society GuidelinesClinical Management and treatment of HIV-infected Adults in Europe. Version 5–42009 Available from: www.eacs.eu. Accessed October 17, 2011
   Google Scholar
• World Health OrganizationAntiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 Revision Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed October 17, 2011
   Google Scholar
• SwensonMCMooresALowAJImproved detection of CXCR4-using HIV by V3 genotyping: application of population based and “deep” sequencing to plasma RNA and proviral DNAJ Acquir Immune Defic Syndr201054550651020512044
   PubMed Web of Science ®Google Scholar
• ParraJPortillaJPulidoFClinical utility of maravirocClin Drug Investig2011318527542
   PubMed Web of Science ®Google Scholar
• PhillipsEMallalSPersonalizing antiretroviral therapy: is it a reality?Personalized Medicine200964393408
   Web of Science ®Google Scholar
• MallalSNolanDWittCAssociation between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirLancet2002359930872773211888582
   PubMed Web of Science ®Google Scholar
• HetheringtonSHughesARMostellerMGenetic variation in HLA-B region and hypersensitivity reactions to abacavirLancet200235993121121112211943262
   PubMed Web of Science ®Google Scholar
• PhillipsEMallalSSuccessful translation of pharmacogenetics into the clinic: the abacavir exampleMol Diagn Ther20091311919351209
   PubMed Web of Science ®Google Scholar
• FigueroaSCde GattaMFGarciaLHThe convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapyTher Drug Monit201032557958520720517
   PubMed Web of Science ®Google Scholar
• MarzoliniCTelentiADecosterdLAGreubGBioliazJBuclinTEfavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patientsAIDS2001151717511192870
   PubMed Web of Science ®Google Scholar
• Arab-alameddineMDi IulioJBuclinTPharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1 infected individualsClin Pharmcol Ther2009855485494
   Web of Science ®Google Scholar
• Di IulioJFayetAArab-AlameddineMIn vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 functionPharmacogen Genomics2009194300309
   PubMed Web of Science ®Google Scholar
• KwaraALarteyMSagoeKWRzekNLCourtMHCYP2B6(c.516 G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patientsBr J Clin Pharmacol200967442743619371316
   PubMed Web of Science ®Google Scholar
• KwaraALarteyMSagoeKWKenuECourtMHCYP2B6, CYP2A6 and UGT2B7 polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsAIDS200923162101210619779319
   PubMed Web of Science ®Google Scholar
• OgburnETJonesDRMastersARXuCGuoYDestaZEfavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylaitonDrug Metab Dispos20103871218122920335270
   PubMed Web of Science ®Google Scholar
• BelangerASCaronPHarveyMZimmermanPAMehlotraRKGuillemetteCGlururonidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudineDrug Metab Dispos20093791793179619487252
   PubMed Web of Science ®Google Scholar
• DestaASausseleTWardBImpact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitroPharmacogenomics20078654755817559344
   PubMed Web of Science ®Google Scholar
• ZhangHSridarCKenaanCAmunugamaHBallouDPHollenbergPFPolymorphic variants of Cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450 reductase complexJ Pharmacol Exp Ther2001338380380921659470
   PubMed Web of Science ®Google Scholar
• NyakutiraCRoshammarDChigutsaEHigh prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in ZimbabweEur J Clin Pharmacol200864435736518057928
   PubMed Web of Science ®Google Scholar
• MehlotraRKBockarieMJZimmermanPACYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatmentBr J Clin Pharmacol200764339139517391322
   PubMed Web of Science ®Google Scholar
• RakhmaninaNYvan den AnkerJNEfavirenz in the therapy of HIV infectionExpert Opin Metab Drug Metab Toxicol20106195103
   PubMed Web of Science ®Google Scholar
• GatanagaHHayashidaTTsuchiyaKSuccessful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and *26Clin Infect Dis20074591230123717918089
   PubMed Web of Science ®Google Scholar
• RibaudoHJLiuHSchwabMEffect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group studyJ Infect Dis2010202571772220662624
   PubMed Web of Science ®Google Scholar
• ElensLVandercamBYombiJCLisonDWallemacqPHaufroidVInfluence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1 infected patientsPharmacogenomics20101191223123420860463
   PubMed Web of Science ®Google Scholar
• WyenCHendraHVogelMImpact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsJ Antimicrob Chemother200861491491818281305
   PubMed Web of Science ®Google Scholar
• PenzakSRKabuyeGMugyenyiPCytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in UgandaHIV Med200782869117352764
   PubMed Web of Science ®Google Scholar
• LegerPDillinghamRBeauhamaisCACYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au- Prince, HaitiJ Infect Dis2009200695596419659438
   PubMed Web of Science ®Google Scholar
• MahunguTSmithCTurnerFCytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse populationHIV Med200910531031719228205
   PubMed Web of Science ®Google Scholar
• SaitohASarlesECapparelliECYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected childrenAIDS200721162191219918090046
   PubMed Web of Science ®Google Scholar
• RibaudoHJHaasDWTierneyCPharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyClin Infect Dis200642340140716392089
   PubMed Web of Science ®Google Scholar
• HaasDWRibaudoHJKimRBPharmacogenetics of efavirenz and central nervous sytem side effects: an Adult AIDS Clinical Trials Group StudyAIDS200418182391400015622315
   PubMed Web of Science ®Google Scholar
• RamachandranGHemanth KumarAKRajasekaranSCYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodefiency virus-infected patients in South IndiaAntimicrob Agents Chemother200953386386819124658
   PubMed Web of Science ®Google Scholar
• RotgerMColomboSFurrerHInfluence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patientsPharmacogent Genomics200515115
   PubMedGoogle Scholar
• RamachandranGRameshKHemanth KumarAKAssociation of high T allele frequence of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapineJ Antimicrob Chemother200963484184319218571
   PubMed Web of Science ®Google Scholar
• TsuchiyaKGatanagaHTachikawaNHomozygous CYP2B6*6(Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochem Biophys Res Commun200431941322132615194512
   PubMed Web of Science ®Google Scholar
• HaasDWGebretsadikTMayoGAssociations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African AmericansJ Infect Dis2009199687288019239339
   PubMed Web of Science ®Google Scholar
• ChenJSunJMaQCYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patientsTher Drug Monit201032557357820625352
   PubMed Web of Science ®Google Scholar
• WangJSonnerborgARaneAIdentification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenzPharmacogenetic Genomics2006163191198
   PubMed Web of Science ®Google Scholar
• MukonzoJKRoshammarDWaakoPA novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in UgandansBr J Clin Pharmacol200968569069619916993
   PubMed Web of Science ®Google Scholar
• RotgerMTegudeHColomboSPredictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individualsClin Pharmacol Ther200781455756617235330
   PubMed Web of Science ®Google Scholar
• RotgerMSaumoyMZhangKPartial deletion of CYP2B6 owing to unequal crossover with CYP2B7Pharmacogenet Genomics2007171088589017885627
   PubMed Web of Science ®Google Scholar
• CarrDFla PorteCJMirmohamedMOwenACortesCPHaplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohortJ Antimicrob Chemother20106591889189320639527
   PubMed Web of Science ®Google Scholar
• HaasDWSmeatonLMShaferRWPharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group StudyJ Infect Dis2005192111931194216267764
   PubMed Web of Science ®Google Scholar
• MotsingerAARitchieMDShaferRWMultilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group studyPharmacogent Genomics20061611837845
   Web of Science ®Google Scholar
• FellayJMarzoliniCMeadenERResponse to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyLancet20022599300303611809184
   PubMed Web of Science ®Google Scholar
• RekicDRoshammarDMukonzoJAshtonMIn silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotypeBr J Clin Pharmacol201171453654321395646
   PubMed Web of Science ®Google Scholar
• KawaraALarteyMSagoeKWCourtMHParadoxically elevated efavirenz concentrations in HIV/tuberculosis co-infected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapyAIDS201125338839021150552
   PubMed Web of Science ®Google Scholar
• MarzoliniCPausEBuclinTKimRBPolymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevanceClin Pharmacol Ther2004751133314749689
   PubMed Web of Science ®Google Scholar
• ZhuDTaguchi-NakamuraHGotoMInfluence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular exposure of nelfinavir and its clinical implication for highly active antiretroviral therapyAntivir Ther20049692993515651752
   PubMed Web of Science ®Google Scholar
• WinzerRLangmannPZillyMNo influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatmentEur J Med Res200381253153414711599
   PubMed Web of Science ®Google Scholar
• BrummeZLDongWWChanKJInfluence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy responseAIDS200317220120812545080
   PubMed Web of Science ®Google Scholar
• AdamsJPatelNMankaryousNNonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agentsAnn Pharmacother20104415716519996323
   PubMed Web of Science ®Google Scholar
• LubomirovRRotgerMFayetAPharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals [abstract]Proceedings of the 18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27–March 2, 2011Boston, MA2011479
   Google Scholar
• SiccardiMD'AvolioABaiettoLAssociation of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396 C>T) with reduced concentrations of unboosted atazanavirClin Infect Dis20084791222122518831695
   PubMed Web of Science ®Google Scholar
• ShipaniASiccardiMD'AvolioAPopulation pharmacokinetic modelling of the association between 63396 C>T pregnane X receptor polymorphism and unboosted atazanavir clearanceAntimicrob Agents Chemother201054125242525020921307
   PubMed Web of Science ®Google Scholar
• SvardJSpiersJPMulcahyFHennessyMNuclear Receptor-Mediated Induction of CYP450 by Antiretrovirals: Functional Consequences of N1I2(PXR) Polymorphisms and Differential Prevalence in Whites and Sub-Saharan AfricansJ Acquir Immune Defic Syndr201055553654920861742
   PubMed Web of Science ®Google Scholar
• HartkoornRCKwanWSShallcrossVHIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsPharmacogenet Genomics201020211212020051929
   PubMed Web of Science ®Google Scholar
• KohlrauschFBde Cassia EstrelaRBarrosoPFSuarez-KurtzGThe impact of SLCO1B1 polymorphisms on the plasma concentrations of lopinavir and ritonavir in HIV-infected menBr J Clin Pharmacol2010691959820078617
   PubMed Web of Science ®Google Scholar
• LubomirovRdi IulioJFayetAADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir co-formulated with ritonavirPharmacogenet Genomics201020421723020139798
   PubMed Web of Science ®Google Scholar
• WenningLAPetryASKostJTPharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsClin Pharmacol Ther200985662362719279563
   PubMed Web of Science ®Google Scholar
• FakenheuerGNelsonMLazzarinASubgroup analysis of maraviroc in previously treated R5 HIV-1 infectionN Eng J Med20083591414421455
   Web of Science ®Google Scholar
• SymondsWCutrellAEdwardsMRisk factor analysis of hypersensitivity reactions to abacavirClin Ther200224456557312017401
   PubMed Web of Science ®Google Scholar
• PeyieereHNicolasJSiffertMHypersensitivity related to abacavir in two members of a familyAnn Pharmacother200135101291129211675863
   PubMed Web of Science ®Google Scholar
• HughesARMostellerNBansalATAssociation of genetic variation in HLA-B region with hypersensitivity to abacavir in some, but not all, populationsPharmacogenomics20045220321115016610
   PubMed Web of Science ®Google Scholar
• DejesusEHerreeraGTeofiloEAbacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adultsClin Infect Dis20043971038104615472858
   PubMed Web of Science ®Google Scholar
• GuilickRRibaudoHShikumaCMThree-versus four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trialJAMA2006296776978116905783
   PubMed Web of Science ®Google Scholar
• Dart Trial TeamTwenty-four week safety and tolerability of nevirapine vs abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)Trop Med Int Health2008131616
   Web of Science ®Google Scholar
• HernandezJCutrellABonnyTDiagnosis of abacavir hypersensitivity reactions among patients receiving abacavir in two blinded studiesAntivir Ther20038L88
   Web of Science ®Google Scholar
• PhillipsEJSullivanJRKnowlesRShearNHUtility of patch testing in patients with hypersensitivity reaction associated with abacavirAIDS200216162223222512409746
   PubMed Web of Science ®Google Scholar
• PhillipsEJWongGAKaulRClinical and immunogenetic correlates of abacavir hypersensitivityAIDS200519997998115905681
   PubMed Web of Science ®Google Scholar
• ShearNHMilipiedBBruynzeelDPPhillipsEA review of drug patch testing and implications for HIV cliniciansAIDS2008229999100718520343
   PubMed Web of Science ®Google Scholar
• MallalSPhillipsECarosiGHLA-B*5701screening for hypersensitivity to abacavirN Engl J Med2008358656857918256392
   PubMed Web of Science ®Google Scholar
• SaagMBaluRPhillipsEHigh sensitivity of human leukocyte antigen-B*5701 as a marker for immunogenetically confirmed abacavir hypersensitivity in white and black patientsClin Infect Dis20084671111111818444831
   PubMed Web of Science ®Google Scholar
• RauchANolanDMartinAProspective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort studyClin Infect Dis20064319910216758424
   PubMed Web of Science ®Google Scholar
• ZucmanDTruchisPMajerholcCProspective genetic screening for human leuckocyte antigen-B*5701 avoid abacavir hypersensitivity in the ethnically mixed French HIV populationJ Acquir Immune Defic Syndr20074511317356469
   PubMed Web of Science ®Google Scholar
• ReevesIChurchillDFisherMScreening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactionsAntiviral Ther200611L11
   Web of Science ®Google Scholar
• TrottierBThomasRNguyenVKMachoufNHow effectively HLA screening can reduce the early discontinuation of abacavir in real life [abstract]Presented at the International AIDS Society MeetingJuly 22–25, 2007Sydney, Australia2007 MOPEB002
   Google Scholar
• LalondeRGThomasRRachlisASuccessful implementation of a national HLA-B*5701 genetic testing service in CanadaTissue Antigens2009751121819843279
   PubMedGoogle Scholar
• WatersLJMandaliaSGazzardBProspective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experienceAIDS200721182533253418025891
   PubMed Web of Science ®Google Scholar
• YoungBSquiresKPatelPFirst large multicentre open-label study utilizing HLA-B*5701screening for abacavir hypersensitivity in North AmericaAIDS200822131673167518670229
   PubMed Web of Science ®Google Scholar
• MartinAMNolanDGaudieriSPredisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variantProc Natl Acad Sci U S A2004101124180418515024131
   PubMed Web of Science ®Google Scholar
• ChessmanDKostenkoLLethborgTHuman leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivityImmunity200828682283218549801
   PubMed Web of Science ®Google Scholar
• MartinAMNolanDMallalSHLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typingTissue Antigens200565657157415896207
   PubMedGoogle Scholar
• HammondEMamotteCNolanDHLA-B*5701 typing: evaluation of an allele-specific polymerase chain melting assayTissue Antigens2007701586117559582
   PubMedGoogle Scholar
• MartinAMKruegerRAlmeidaCAA sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndromePharmacogenet Genomics200616535335716609367
   PubMed Web of Science ®Google Scholar
• Dello RussoCLisiLLofaroANovel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*5701 detection by real-time PCRPharmacogenomics201112456757621521028
   PubMed Web of Science ®Google Scholar
• KostenkoLKjer-NielsenLNicholsonIRapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivityTissue Antigens2011781112021501118
   PubMedGoogle Scholar
• HammondEAlmeidaCAMamotteCExternal quality assessment of HLA-B*5701 reporting and international multicentre surveyAntivir Ther20071271027103218018760
   PubMed Web of Science ®Google Scholar
• PhillipsEMallalSDrug hypersensitivity in HIVCurr Opin Allergy Clin Immunol20077432433017620824
   PubMed Web of Science ®Google Scholar
• MartinAMNolanDJamesIPredisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T cell countsAIDS2005191979915627041
   PubMed Web of Science ®Google Scholar
• LitteraRCarcassiCMasalaAHLA-dependent hypersensitivity to nevirapine in Sardinian HIV patientsAIDS200620121621162616868443
   PubMed Web of Science ®Google Scholar
• GatanagaHYazakiHTanumaJHLA-Cw8 primarily associated with hypersensitivity to nevirapineAIDS200721226426517197830
   PubMed Web of Science ®Google Scholar
• ChantarangsuSMushirodaTMahasirimongkolSHLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patientsPharmacogent Genomics2009192139146
   PubMed Web of Science ®Google Scholar
• PhillipsELucasMKeaneNLucasAMcKinnonEMallalSHLA-B*35 is associated with nevirapine hypersensitivity in the contemporary Western Australian HIV cohort studyEur Ann Allergy Clin Immunol20104248
   Google Scholar
• YuanJGuoSHallDToxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian and European descentAIDS201125101271128021505298
   PubMed Web of Science ®Google Scholar
• HaasDWBartlettJAAndersonJWPharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaborationClin Infect Dis200643678378616912957
   PubMed Web of Science ®Google Scholar
• RitchieMDHaasDWMotsingerAADrug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicityClin Infect Dis200643677978216912956
   PubMed Web of Science ®Google Scholar
• CiccacciCBorgianiPCeffaSNevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from MozambiquePharmacogenomics2010111233120017669
   PubMed Web of Science ®Google Scholar
• PhillipsEBartlettJSanneIAssociations between HLA-DRB1*0102, HLA-B*5801 and hepatotoxicity in patients who initiated nevirapine containing regimens in South Africa [abstract]Proceedings of the 18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27–March 1, 2011Boston, MA2011949
   Google Scholar
• VitezicaZGMilipiedBLonjouCHLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenzAIDS200822454054118301070
   PubMed Web of Science ®Google Scholar
• DalakasMCPeripheral neuropathy and antiretroviral drugsJ Peripher Nerv Syst200161142011293802
   PubMed Web of Science ®Google Scholar
• HulganTHaasDWHainesJLMitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group studyAIDS200519131341134916103764
   PubMed Web of Science ®Google Scholar
• CanterJAHaasDWKallianpurARThe mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathyPharmacogenomics J200881717717684475
   PubMed Web of Science ®Google Scholar
• KallianpurARHulganTCanterJAHemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapyAIDS200620111503151316847405
   PubMed Web of Science ®Google Scholar
• ChewCSCherryCLImranDTumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patientsTissue Antigens201177212613020887379
   PubMedGoogle Scholar
• CherryCLRosenowAAffandiJSCytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts and individuals NRTI-SN riskAIDS Res Hum Retroviruses200824211712318240960
   PubMed Web of Science ®Google Scholar
• AfandiJSPricePImranDCan we predict neuropathy risk before stavudine prescription in a resource-limited setting?AIDS Res Hum Retroviruses20082411281128418834321
   PubMed Web of Science ®Google Scholar
• YamanakaHGatanagaHKosalaraksaPNovel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatmentJ Infect Dis2007195101419142517436221
   PubMed Web of Science ®Google Scholar
• NolanDMooreCCastleyATumour necrosis factor-alpha gene 239G/A promoter polymorphism is associated with a more rapid onset of lipodystrophyAIDS200317112112312478078
   PubMed Web of Science ®Google Scholar
• MaherBAlfrevicAVilarFJTNF-alpha promoter region gene polymoprhisms in HIV-positive patients with lipodystrophyAIDS200316152013201812370499
   PubMed Web of Science ®Google Scholar
• HendricksonSLKingsleyLARuiz-PesiniEMitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapyJ Acquir Immune Defic Syndr200951211111619339895
   PubMed Web of Science ®Google Scholar
• HulganTTebasPCanterJAHemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapyJ Infect Dis2008197685886618419350
   PubMed Web of Science ®Google Scholar
• AsensiVRegoCMontesAHIL-1beta (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndromeGent Med2008103215223
   Google Scholar
• RanadeKGeeseWJNoorMGenetic analysis implicates resistin in HIV lipodystrophyAIDS200822131561156818670214
   PubMed Web of Science ®Google Scholar
• WangsomboonsiriWMahasirimongkolSChantarangsuSAssociation between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimenClin Infect Dis201050459760420073992
   PubMed Web of Science ®Google Scholar
• NelsonMKatlamaCMontanerJSThe safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsAIDS200721101273128117545703
   PubMed Web of Science ®Google Scholar
• CooperRDWiebeNSmithNKeiserPNaickerSTonelliMSystematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patientsClin Infect Dis201051549650520673002
   PubMed Web of Science ®Google Scholar
• GoicoecheaMLiuSBestBGreater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor based therapyJournal of Inf Dis20081971102108
   PubMed Web of Science ®Google Scholar
• KiserJJAquilanteCLAndersonPLKingTMCartenMLFletcherCVClinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patientsClin Pharmacol Ther200883226527217597712
   PubMed Web of Science ®Google Scholar
• IzzedineHHulotJSVillardEAssociation between ABBCC2 gene haplotypes and tenofovir-induced proximal tubulopathyJ Infect Dis2006194111481149117083032
   PubMed Web of Science ®Google Scholar
• Rodriguez-NovoaSLabargaPSorianoVPredictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic studyClin Infect Dis20094811E108E11619400747
   PubMed Web of Science ®Google Scholar
• PushpakomSPLiptrottNJRodrigues-NovoaSGenetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionJ Infect Dis2011204114515321628669
   PubMed Web of Science ®Google Scholar
• ZuckerSCQinXRousterSCMechanism of indinavir-induced hyperbilirubinemiaProc Natl Acad Sci U S A20019822126711267611606755
   PubMed Web of Science ®Google Scholar
• SolasCGagnieuMCRavauxIPopulation pharmacokinetics of atazanavir in human immunodeficiency virus-infected patientsTher Drug Monit200830667067318806695
   PubMed Web of Science ®Google Scholar
• BarriosARendonALGallegoOPredictors of virological response to atazanavir in protease inhibitor exposed patientsHIV Clin Trials20045420120515472794
   PubMed Web of Science ®Google Scholar
• StrassburgCPPharmacogenetics of Gilberts's syndromePharmacogenomics20089670371518518849
   PubMed Web of Science ®Google Scholar
• RotgerMTaffePBleiberGGilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemiaJ Infect Dis200519281381138616170755
   PubMed Web of Science ®Google Scholar
• Rodriguez-NovoaSMartin-CarboneroLBarreiroPGenetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemiaAIDS2007211414617148966
   PubMed Web of Science ®Google Scholar
• ParkWBChoePGSongKHGenetic factors influencing severe atazanavir-associated hyperbilirbuinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequencyClin Infect Dis201051110110620504240
   PubMed Web of Science ®Google Scholar
• KummerOMossdorfEBattegayMTreatment of an atazanavir associated grade 4 hyperbilirubinemia with efavirenzGut200756101477147817872579
   PubMed Web of Science ®Google Scholar
• Rodriguez-NovoaSBarreiroPRendonAPlasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435 C-->T polymorphism at the multidrug resistance gene 1Clin Infect Dis200642229129516355344
   PubMed Web of Science ®Google Scholar
• LubomirovRColomboSdi IulioJAssociation of pharmacogenetic markers with premature discontinuation of first-line anti HIV therapy: an observational cohort studyJ Infect Dis2011203224625721288825
   PubMed Web of Science ®Google Scholar
• ArnedoMTarffePSahliRContribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapyPharmacogenet Genomics200717975576417700364
   PubMed Web of Science ®Google Scholar
• RotgerMBayardCTaffePContribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal studyCirc Cardiovasc Genet20092662162820031643
   PubMedGoogle Scholar
• ChangSYKoWSKaoJTAssociation of single-nucleotide polymorphism 3 and c.553G >T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in TaiwanClin Infect Dis200948683283519187029
   PubMed Web of Science ®Google Scholar
• GrunfeldCKotlerDPHamadehRTierneyAWangJPiersonRNHypertriglyceridemia in the acquired immunodeficiency syndromeAm J Med198986127312910092
   PubMed Web of Science ®Google Scholar
• TarrPETaffePBleiberGModeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disordersJ Infect Dis200519191419142615809899
   PubMed Web of Science ®Google Scholar
• TarrPERotgerMTelentiADyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomicsPharmacogenomics201011458759420350140
   PubMed Web of Science ®Google Scholar
• CespedesMSAbergJANeuropsychiatric complications of antiretroviral therapyDrug Saf2006291086587416970510
   PubMed Web of Science ®Google Scholar
• Van LuiriMBannisterWPMocroftAAbsence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA studyAntivir Ther2009141758319320239
   PubMed Web of Science ®Google Scholar
• WyenCHendraHSiccardiMCytochrome P450 2B6(CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimensJ Antimicrob Chemother20116692092209821715435
   PubMed Web of Science ®Google Scholar
• BurgerDHugenPReissPTherapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1 infected individualsAIDS20031781157116512819517
   PubMed Web of Science ®Google Scholar
• DemeterLMMukherjeeALDiFrancescoRThe design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patientsHIV Clin Trials200891617218215983
   PubMed Web of Science ®Google Scholar
• BestBMStekAMMirochnickMLopinavir tablet pharmacokinetics with an increased dose during pregnancyJ Acquir Immune Defic Syndr201054438138820632458
   PubMed Web of Science ®Google Scholar
• MirochnickMCapparelliEPharmacokinetics of antiretrovirals in pregnant womenClin Pharmacokinet200443151071108715568888
   PubMed Web of Science ®Google Scholar
• http://www.hiv-pharmacogenomics.org/pdf/ref_tbl_pharmaco/HIV_Pharmacogenomics_reference_table.pdf. Accessed October 11, 2011
   Google Scholar
• PhillipsEJMallalSAPharmacogenetics of drug hypersensitivityPharmacogenomics201011797398720602616
   PubMed Web of Science ®Google Scholar
• GeDFellayJThompsonAJGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature2009461726239940119684573
   PubMed Web of Science ®Google Scholar
• TanakaYNishidaNSugiyamaMGenome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CNat Gent2009411011051109
   PubMed Web of Science ®Google Scholar
• SuppiahVMoldovanMAhlenstielGIL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyNat Genet20094111100110419749758
   PubMed Web of Science ®Google Scholar
• BachmannHSiffertWSkaletz-RorowskiAImpact of IL28B polymorphisms on sustained virologic response of HCV/HIV co-infected patients [abstract]Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections2011 Feb 27–Mar 1Boston, MA2011946
   Google Scholar
• LabargaPBarreiroPMiraJAImpact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-co-infected patients with prior nonresponse or relapseAIDS20112581131113321537116
   PubMed Web of Science ®Google Scholar